Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

230.63 +5.08 (+2.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Natera (NASDAQ:NTRA) and the... 
Via StockStory
Topics Artificial Intelligence
News headline image
Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗
Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation. 
Via Benzinga
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Natera? ↗
 
Via Benzinga
News headline image
1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Stocks
News headline image
2 Surging Stocks with Impressive Fundamentals and 1 We Question
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
Natera (NTRA) Q3 2025 Earnings Call Transcript ↗
Natera (NTRA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue guidance of $2.22... 
Via StockStory
News headline image
Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance ↗
Natera (NTRA) Q3 2025 results beat revenue forecasts with $592.2M, driven by strong oncology test growth. The company raised its full-year 2025 guidance. 
Via Chartmill
News headline image
Natera (NASDAQ:NTRA) Delivers Impressive Q3
Genetic testing company Natera (NASDAQ:NTRA). reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 34.7% year on year to $592.2 million. The company’s full-year revenue... 
Via StockStory
News headline image
Natera (NTRA) Reports Earnings Tomorrow: What To Expect
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings this Thursday after the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 We Ignore
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
A Glimpse Into The Expert Outlook On Natera Through 8 Analysts ↗
 
Via Benzinga
News headline image
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Are Natera (NTRA) Shares Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.2% in the afternoon session after the company announced promising results from its phase 3 IMvigor011 clinical trial for its Signatera... 
Via StockStory
Topics Intellectual Property
News headline image
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Retirement
News headline image
2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Stocks making big moves yesterday: Acadia Healthcare, Tesla, THOR Industries, Natera, and P10
Check out the companies making headlines yesterday: 
Via StockStory
Topics Electric Vehicles
News headline image
Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Why Natera (NTRA) Stock Is Down Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.5% in the afternoon session after Wells Fargo & Company initiated coverage on the stock with a neutral "equal weight" rating and set a... 
Via StockStory
Topics Artificial Intelligence Lawsuit
News headline image
Deep Dive Into Natera Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
If You Invested $100 In Natera Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
2 Unprofitable Stocks on Our Watchlist and 1 We Ignore
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
News headline image
Why Natera (NTRA) Stock Is Trading Lower Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v.... 
Via StockStory
Topics Artificial Intelligence Lawsuit
News headline image
Why Natera (NTRA) Shares Are Falling Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood... 
Via StockStory
Topics Intellectual Property
News headline image
3 Reasons We’re Fans of Natera (NTRA)
Since September 2020, the S&P 500 has delivered a total return of 94.8%. But one standout stock has doubled the market - over the past five years, Natera has surged 186% to $176.64 per share. Its... 
Via StockStory
Topics Stocks
News headline image
1 Cash-Producing Stock to Own for Decades and 2 We Find Risky
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Supply Chain
News headline image
Why Natera (NTRA) Stock Is Down Today
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing patent litigation with competitor... 
Via StockStory
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.